The company’s business is focused on the discovery and development of novel lead structures based on
cyanobacterial Natural Products (NP). Using its proprietary strain collection with more than 1.100 NP
producer strains and its NP libraries with more than 5,000 novel compounds, Cyano Biotech identifies novel
leads, optimizes their pharmacological properties by proprietary techniques and generates recombinant microbial
producer strains delivering high yields of target compounds. Beside its own drug discovery program,
Cyano Biotech collaborates with international pharmaceutical and biotech companies.
The company’s drug discovery programs are dedicated to three indications:
Why do we focus on these indications? Cyanobacteria produce highly potent toxins in order to be effective in an
aquatic environment
where compounds get diluted fast. They have to fight viruses, bacteria, fungi, plankton and found numerous
strategies to win. Due to their habitat they handle easily UV radiation, oxidative stress and dehydration.
All mostly mediated by bioactive natural products.
Our current focus lies on the development & production of novel payloads for antibody-drug conjugates.
We have developed a proprietary platform technology that allows for:
By using our platform technology we have recently produced modified/optimized microcystins with anchor groups comprising different kinds of click chemistry for their efficient coupling to linkers of MABs towards novel, potent and selective antibody-drug conjugates.
